tiprankstipranks
Trending News
More News >
Phathom Pharmaceuticals, Inc. (PHAT)
:PHAT
US Market

Phathom Pharmaceuticals (PHAT) Ownership - Who Owns Phathom Pharmaceuticals?

Compare
402 Followers

Phathom Pharmaceuticals (PHAT) Ownership Overview

12.74%17.13%10.79%8.07%51.28%
12.74% Insiders
10.79% Other Institutional Investors
8.07% ETFs
51.28% Public Companies and
Individual Investors
The ownership structure of Phathom Pharmaceuticals (PHAT) stock is a mix of institutional, retail, and individual investors. Approximately 35.98% of the company’s stock is owned by Institutional Investors, 12.74% is owned by Insiders, and 51.28% is owned by Public Companies and Individual Investors.
The ownership structure of Phathom Pharmaceuticals (PHAT) stock is a mix of institutional, retail, and individual investors. Approximately 27.92% of the company’s stock is owned by Institutional Investors, 12.74% is owned by Insiders, and 8.07% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date
Name
Activity
Value
Apr 08, 2025
xxxxxxxxxxxxx
$16735
Mar 17, 2025
xxxxxxxxxxxxx
$44200
Dec 20, 2024
xxxxxxxxxxxxx
$10328
Dec 20, 2024
xxxxxxxxxxxxx
$8944

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Dec 31, 2024
xxxxxxxxxxxxx
$337873
Dec 31, 2024
xxxxxxxxxxxxx
$1177919
Dec 31, 2024
xxxxxxxxxxxxx
$8133739

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
5,863,424Insider8.42%27,968,532
2,634,691Institution3.78%12,567,476
2,303,227Institution3.31%10,986,393
1,835,858Institution2.64%8,757,043
1,781,345Institution2.56%8,497,016
1,579,095Institution2.27%7,532,283
1,379,470Institution1.98%6,580,072
1,231,255Insider1.77%5,873,086
1,208,300Institution1.74%5,763,591
1,101,868Insider1.58%5,255,910

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
2,303,227Institution3.31%10,986,393
1,781,345Institution2.56%8,497,016
1,579,095Institution2.27%7,532,283
1,379,470Institution1.98%6,580,072
1,208,300Institution1.74%5,763,591
746,710Institution1.07%3,561,807
464,839Institution0.67%2,217,282
426,394Institution0.61%2,033,899
389,709Institution0.56%1,858,912
253,000Institution0.36%1,206,810

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
1,588,583Institution2.28%8,768,978
1,002,976Institution1.44%4,784,196
716,484Institution1.03%3,954,992
681,935Institution0.98%3,252,830
283,970Institution0.41%1,354,537
242,235Institution0.35%1,155,461
208,797Institution0.30%966,730
178,322Institution0.26%984,337
119,583Institution0.17%660,098
87,267Institution0.13%416,264

FAQ

Who Owns Phathom Pharmaceuticals, Inc. (PHAT)?
According to the latest TipRanks data, approximately 10.79% of the company's stock is held by institutional investors, 12.74% is held by insiders, and 51.28% is held by retail investors.
    What percentage of Phathom Pharmaceuticals, Inc. (PHAT) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 10.79% of Phathom Pharmaceuticals, Inc. (PHAT) stock is held by institutional investors.
      What percentage of Phathom Pharmaceuticals, Inc. (PHAT) stock is held by retail investors?
      According to the latest TipRanks data, approximately 51.28% of Phathom Pharmaceuticals, Inc. (PHAT) stock is held by retail investors.
        Who owns the most shares of Phathom Pharmaceuticals, Inc. (PHAT)?
        James Topper owns the most shares of Phathom Pharmaceuticals, Inc. (PHAT).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis